Moreover, as senolytics were found therapeutic against idiopathic pulmonary fibrosis, a BRD4-associated condition, these agents may be helpful to SRD patients (Tang et al., 2013; Acharya et al., 2021). The gene discussed is BRD4; the disease is dopa-responsive dystonia due to sepiapterin reductase deficiency.